A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This is a randomized, double‐blind study of MSDC‐0602K or placebo given orally once daily to subjects with pre‐T2D or T2D and evidence of NAFLD/NASH. Visits will include a Screening Period, a minimum Treatment of 26 weeks, and a Long‐Term Follow‐up Period during which subjects will continue taking assigned treatment. Safety will be assessed by periodic measurement of vital signs, physical examinations, blood laboratory analyses, and the occurrence of adverse events.
Epistemonikos ID: 37893273f46159525a075e067618629e72d4b56e
First added on: May 22, 2024